Oncolytics Biotech (ONCY) Shares Outstanding (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Shares Outstanding (Entity) of $910.7 million for Q4 2025, up 25.33% year-over-year from $726.6 million in Q4 2024, and down 5.39% quarter-over-quarter from $962.5 million in Q3 2025.
Oncolytics Biotech (ONCY) Shares Outstanding (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Shares Outstanding (Entity) for 17 consecutive years, with $910.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 25.33% year-over-year to $910.7 million; the TTM figure through Dec 2025 stood at $910.7 million (up 25.33% YoY), while the FY2025 annual figure was $910.7 million, up 25.33% from the prior year.
- Shares Outstanding (Entity) fell to $910.7 million in Q4 2025 per ONCY's latest filing, from $962.5 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $962.5 million in Q3 2025 and bottomed at $471.8 million in Q1 2021.
- Historically, Shares Outstanding (Entity) has averaged $655.7 million across 5 years, with a median of $622.4 million in 2023.
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) surged 38.48% — and 2022, when it advanced 6.12%.
- Oncolytics Biotech's Shares Outstanding (Entity) stood at $508.4 million in 2021, then increased by 8.44% to $551.3 million in 2022, then climbed by 16.53% to $642.4 million in 2023, then rose by 13.1% to $726.6 million in 2024, then rose by 25.33% to $910.7 million in 2025.
- Business Quant data shows ONCY's Shares Outstanding (Entity) at $910.7 million in Q4 2025, $962.5 million in Q3 2025, and $834.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | 119.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.86 Mn |
| Dec 31, 2025 | 95.86 Mn |
| Sep 30, 2025 | 101.32 Mn |
| Jun 30, 2025 | 87.83 Mn |
| Mar 31, 2025 | 84.63 Mn |
| Dec 31, 2024 | 76.48 Mn |
| Sep 30, 2024 | 77.02 Mn |
| Jun 30, 2024 | 75.67 Mn |
| Mar 31, 2024 | 75.24 Mn |
| Dec 31, 2023 | 67.62 Mn |
| Sep 30, 2023 | 69.80 Mn |
| Jun 30, 2023 | 63.41 Mn |
| Mar 31, 2023 | 62.34 Mn |
| Dec 31, 2022 | 58.03 Mn |
| Sep 30, 2022 | 58.33 Mn |
| Jun 30, 2022 | 57.67 Mn |
| Mar 31, 2022 | 56.58 Mn |
| Dec 31, 2021 | 53.51 Mn |
| Sep 30, 2021 | 54.96 Mn |
| Jun 30, 2021 | 54.33 Mn |